Barrie March
Research Subjects
Research Interests
Barrie March has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Tara Cardi
1 shared publication
Latest Publications
- 23 October 2009
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 18 (12) , 1807-1815
Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals
Objective: To characterize the effects of a sustained-release formulation of fampridine (fampridine-SR) on QT interval in healthy subjects. Methods: In a double-blind, double-dummy trial, healthy subjects were randomized to 5 days treatment with fampridine-SR at therapeutic (10 mg twice daily) or supratherapeutic (30 mg twice daily) doses, placebo or moxifloxacin (400 mg on treatment day 5). Digital 12-lead electrocardiograms were recorded before treatment and on day 5; blood samples determined fampridine concentrations. Central tendency analysis determined whether the upper limit of the CI for the QT (individual-corrected QT; QTcI) interval change exceeded 10 ms. Outlier analysis determined new-onset QT (corrected QT; QTc) intervals; maximum change in QTc from baseline of 30 – 60 ms and maximum change from baseline ≥ 60 ms. The relationship between pharmacokinetic parameters and QTcI values is explored. Results: Moxifloxacin was associated with a QTcI interval increase > 5 ms at 7 time points; no increas...
- 23 October 2009
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 18 (12) , 1807-1815
Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals
Objective: To characterize the effects of a sustained-release formulation of fampridine (fampridine-SR) on QT interval in healthy subjects. Methods: In a double-blind, double-dummy trial, healthy subjects were randomized to 5 days treatment with fampridine-SR at therapeutic (10 mg twice daily) or supratherapeutic (30 mg twice daily) doses, placebo or moxifloxacin (400 mg on treatment day 5). Digital 12-lead electrocardiograms were recorded before treatment and on day 5; blood samples determined fampridine concentrations. Central tendency analysis determined whether the upper limit of the CI for the QT (individual-corrected QT; QTcI) interval change exceeded 10 ms. Outlier analysis determined new-onset QT (corrected QT; QTc) intervals; maximum change in QTc from baseline of 30 – 60 ms and maximum change from baseline ≥ 60 ms. The relationship between pharmacokinetic parameters and QTcI values is explored. Results: Moxifloxacin was associated with a QTcI interval increase > 5 ms at 7 time points; no increas...